Crizotinib
About
Therapy type: Targeted therapy
Therapy strategy: ALK inhibition, MET inhibition, ROS1 inhibition
Mappings
NCI Thesaurus: Crizotinib (ncit:C74061)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | v::ALK | Non-Small Cell Lung Cancer | Crizotinib | |
| Sensitivity (+) | v::ROS1 | Non-Small Cell Lung Cancer | Crizotinib | |
| Sensitivity (+) | v::ALK | Anaplastic Large Cell Lymphoma | Crizotinib | |
| Sensitivity (+) | v::ALK | Inflammatory Myofibroblastic Tumor | Crizotinib | |
| Sensitivity (+) | v::ALK | Non-Small Cell Lung Cancer | Crizotinib | |
| Sensitivity (+) | v::ALK | Non-Small Cell Lung Cancer | Crizotinib | |
| Sensitivity (+) | v::ROS1 | Non-Small Cell Lung Cancer | Crizotinib | |
| Sensitivity (+) | v::ALK | Anaplastic Large Cell Lymphoma | Crizotinib | |
| Sensitivity (+) | v::ALK | Inflammatory Myofibroblastic Tumor | Crizotinib | |
| Sensitivity (+) | v::ALK | Non-Small Cell Lung Cancer | Crizotinib |